Marshall Wace
SGTX

Marshall Wace’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Marshall Wace’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-290
Closed -$10K – 4278
2021
Q4 		$10K Buy
+290
New +$16.5K ﹤0.01% 3756

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's SGTX Position: Q1 2022 in Review

Marshall Wace sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2022, closing a stake of 290 shares — an estimated $10K sold.

Marshall Wace first reported a position in SGTX in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 48 funds tracked by Wall St. Rank hold SGTX as of Q1 2022.

  • Marshall Wace reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 290 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $10K.
  • Marshall Wace first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Marshall Wace's Sigilon Therapeutics, Inc. Common Stock position peaked at $10K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.